Research
Hormonal
LY3537021 was well tolerated with infrequent gastrointestinal adverse events.
LY3537021 may be a safe option for patients with T2D.
StrongSupportsmedium confidence
LY3537021 was well tolerated with infrequent gastrointestinal adverse events.
Why this rating
Based on the phase 1 randomized controlled trial design.
Source
Long-acting GIPR agonist LY3537021 reduces body weight and fasting blood glucose in patients with T2D: Preclinical development and phase 1 randomized ascending dose studies
William C. Roell et al. · Molecular Metabolism · 2025
DOI 10.1016/j.molmet.2025.102298
rctCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- The long-acting GIPR agonist LY3537021 induced a mean body weight loss of 3.14 kg in participants with T2D compared to 0.36 kg in the placebo group at day 57 (p < 0.05).Strong
- Transient reductions in fasting glucose were observed in participants with T2D, but these were not sustained and not significantly different from placebo at day 29.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →